The bill amends section 2713(a) of the Public Health Service Act to require group health plans and health insurance issuers offering group or individual coverage to provide evidence-based prostate cancer screening for men age 40 and older who are at high risk — without imposing cost-sharing. It inserts a new subparagraph to require coverage for additional preventive services and screenings for prostate cancer specific to this population.
This matters because the measure targets screening access for African‑American men and men with a family history of prostate cancer, groups identified in the bill as having higher incidence and mortality. By eliminating copays, coinsurance, and deductibles for these screenings, the bill shifts financial barriers to insurers and could change screening uptake, diagnostic pathways, and insurer benefit design for men flagged as high-risk.
At a Glance
What It Does
The bill adds a new coverage requirement to the preventive-services statute (42 U.S.C. 300gg‑13(a)), directing plans and issuers to cover additional evidence-based prostate cancer screenings for men aged 40+ at high risk without cost-sharing. It also defines ‘‘men with a family history of prostate cancer’’ and includes a narrow clarification about which USPSTF breast-cancer recommendations remain current.
Who It Affects
Applies to group health plans and health insurance issuers offering group or individual coverage subject to the Public Health Service Act (ERISA‑covered employer plans, state-regulated insurers where preempted rules don’t apply). Affects primary care, urology, and oncology providers who order PSA testing and insurers that must revise coverage and cost-sharing rules for the specified cohort.
Why It Matters
The statute creates a categorical, no-cost-sharing entitlement for a targeted preventive service tied to an age and risk threshold, which can alter benefit design, utilization management, and actuarial assumptions. It also inserts statutory definitions that will guide plan eligibility, documentation, and claim adjudication for prostate screening services.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill rewrites the preventive-services paragraph of the Public Health Service Act to add a targeted no-cost-sharing requirement for prostate screening in men at heightened risk. Rather than simply encouraging clinician discussion, it instructs plans and issuers to cover “additional evidence-based preventive care and screenings” for prostate cancer for men 40 and older who are considered high-risk, and to do so without imposing copays, coinsurance, or deductibles for those services.
To make the requirement administrable, the bill supplies a statutory definition of ‘‘men with a family history of prostate cancer.’’ That definition is broader than some clinical guidelines: it covers first-degree relatives diagnosed with prostate cancer, relatives whose death was due to prostate cancer, relatives diagnosed with cancers associated with increased prostate cancer risk, and relatives with genetic alterations linked to higher risk. Insurers will need to decide what documentation suffices to establish family-history status when adjudicating claims or applying enrollment rules.The text also contains an unusual clause addressing breast-cancer screening: it directs that USPSTF recommendations on breast cancer, mammography, and prevention be treated as current except for recommendations issued in or around November 2009.
Practically, this appears aimed at locking in a prior set of USPSTF guidance for breast screening, which could affect other preventive coverage obligations tied to USPSTF recommendations. Finally, the bill preserves insurer discretion to cover services beyond USPSTF recommendations and clarifies that plans may still offer services not recommended by USPSTF, while setting an effective date for plan years beginning on or after January 1, 2025.
The Five Things You Need to Know
The bill requires coverage without cost-sharing of additional evidence-based prostate cancer preventive services for men age 40 and older who are ‘‘high risk’’ (including African‑American men and men with defined family history).
It adds a statutory, multi-pronged definition of ‘‘men with a family history of prostate cancer’’ limited to first‑degree relatives diagnosed with or deceased from prostate cancer, relatives with cancers associated with higher prostate risk, or relatives with genetic alterations tied to prostate cancer risk.
Coverage must be provided by group health plans and issuers offering group or individual market coverage subject to title XXVII of the Public Health Service Act (i.e.
plans that fall under 42 U.S.C. 300gg–13(a)).
The bill includes a clause treating current USPSTF recommendations on breast cancer screening and mammography as ‘‘the most current’’ except for those issued around November 2009, an anomalous statutory freeze that could affect other preventive coverage mandates tied to USPSTF guidance.
The effective date applies to plan years beginning on or after January 1, 2025, creating near‑term operational timelines for plan benefit design, notices, and claims processing.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Names the Act
This section supplies the short title: ‘‘Prostate‑Specific Antigen Screening for High‑risk Insured Men Act’’ or ‘‘PSA Screening for HIM Act.’
Congressional findings about prostate cancer risk and disparities
The findings catalogue incidence, mortality, survival differences by stage, and higher rates among African‑American men and those with family history. While not operative law, these findings signal legislative intent to prioritize screening for specific subpopulations and frame the health‑equity rationale that will inform regulatory interpretation and enforcement priorities.
Adds targeted preventive‑service coverage requirement
This is the operative change: the bill restructures 2713(a) to insert a new subparagraph (E) requiring plans to cover ‘‘additional evidence‑based preventive care and screenings’’ for prostate cancer for men 40 and older at high risk. Practically, plans must identify which prostate screening services qualify as ‘‘evidence‑based’’ for this cohort and must remove cost-sharing when those services are provided. Insurers will need to map current CPT/HCPCS codes for PSA tests, related lab work, and any guideline‑recommended follow‑ups into covered no‑cost services and update summaries of benefits to reflect the change.
Defines ‘men with a family history of prostate cancer’
The amendment creates a narrow statutory definition limited to first‑degree relatives with prostate cancer diagnosis, death from prostate cancer, associated cancers, or known genetic alterations linked to prostate risk. This shifts a clinical concept into statutory form, requiring plans to develop claim and eligibility criteria (for example, what documentation of a relative’s diagnosis or genetic test result will be required) and possibly to adjust medical-management programs to verify high‑risk status.
Breast‑cancer USPSTF clarification
The bill instructs that, for purposes of this Act and other law, current USPSTF recommendations on breast cancer screening be treated as those issued after November 2009 except for the guidance issued ‘‘in or around November 2009.’’ That language effectively locks in a specific historical posture of USPSTF guidance; regulators and plans will have to reconcile that clause with the usual statutory trigger whereby USPSTF ‘A’ or ‘B’ recommendations establish required coverage.
Rule of construction preserving plan discretion
This provision makes clear that nothing prevents plans from covering services beyond USPSTF recommendations or from covering services not recommended by USPSTF. It preserves insurer flexibility to adopt broader preventive benefits or to decline coverage based on their clinical policies, although the new prostate provision operates as a firm coverage requirement for the defined cohort.
Applies changes to plan years starting on or after Jan 1, 2025
The amendments take effect for plan years beginning on or after January 1, 2025. Compliance will require benefit‑language updates, member notices, and insurer systems changes ahead of those plan‑year starts; the relatively short lead time raises administrative and operational implications for carriers and TPAs.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- High‑risk men (African‑American men and men with the defined family history) — Removes cost-sharing barriers to PSA screening and associated evidence‑based preventive services, likely increasing access to early detection for these populations.
- Primary care and urology clinics serving high‑risk populations — Patients facing fewer financial barriers may seek screening earlier, increasing preventive visit volume and potentially shifting case mix toward earlier‑stage diagnoses.
- Public‑health programs focused on cancer disparities — The targeted coverage aligns federal law with disparity‑reduction goals, enabling programmatic partnerships and outreach that rely on covered services to be effective.
Who Bears the Cost
- Health insurers and self‑insured employers — Must absorb costs of screening and related services without member cost-sharing and update benefits, claims edits, and utilization‑management frameworks to reflect the statutory requirement.
- Third‑party administrators and employer benefits teams — Face administrative burdens to implement eligibility documentation standards, revise summary plan descriptions, and manage member communications within the effective‑date window.
- State insurance regulators and CMS (as applicable) — Will need to interpret the USPSTF clause, issue guidance on acceptable evidence for ‘‘family history,’’ and oversee enforcement, potentially stretching regulatory resources.
Key Issues
The Core Tension
The bill balances two legitimate goals — expanding access to early prostate‑cancer detection for populations with higher mortality, and containing health‑plan costs and clinical overscreening — but it offers no clear mechanism to manage the trade‑off between broader, no‑cost access and the risk of increased low‑value testing, inconsistent eligibility verification, and higher premiums or narrower benefits elsewhere.
Two implementation questions are prominent. First, the statute assigns a preventive‑service duty tied to ‘‘evidence‑based’’ screenings for a demographic cohort but does not identify which specific tests or follow‑up procedures are covered beyond referencing ‘‘prostate cancer screenings.’’ Insurers, providers, and regulators must decide whether the mandate covers only PSA laboratory testing or also includes confirmatory imaging, MRIs, genomic testing, or repeat testing schedules — and whether preauthorization or clinical-appropriateness criteria remain permissible.
That ambiguity creates potential disputes over claims denials, medical‑necessity rules, and provider billing practices.
Second, the family‑history definition is operational but not self‑executing. The bill does not specify what proof a member must submit to demonstrate a qualifying first‑degree relative (medical records, death certificates, genetic test reports) or how often risk status must be reverified.
Insurers could adopt different evidentiary standards, producing uneven access. The USPSTF breast‑screening clause adds another layer of complexity: its odd phrasing appears intended to freeze certain older USPSTF judgments, which could conflict with the normal statutory mechanism that ties coverage to the ‘‘most current’’ USPSTF ‘A’ and ‘B’ recommendations, raising preemption and interpretive questions for regulators and courts.
Finally, there is an actuarial trade‑off. Eliminating cost-sharing for a targeted subgroup will increase utilization among those members and shift costs onto payers and employers.
That can prompt premium adjustments, benefit offsets elsewhere, or stricter utilization controls. Whether the public‑health gains from earlier detection offset higher short‑term screening and diagnostic costs depends on downstream clinical pathways, overdiagnosis rates, and whether newly detected lesions require treatment or active surveillance.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.